140 related articles for article (PubMed ID: 28049894)
1. [Development of New Liposome Targeting Strategies for Application of Disease Therapies].
Shimizu K
Yakugaku Zasshi; 2017; 137(1):43-48. PubMed ID: 28049894
[TBL] [Abstract][Full Text] [Related]
2. Specific delivery of an immunosuppressive drug to splenic B cells by antigen-modified liposomes and its antiallergic effect.
Shimizu K; Miyauchi H; Urakami T; Yamamura-Ichikawa K; Yonezawa S; Asai T; Oku N
J Drug Target; 2016 Nov; 24(9):890-895. PubMed ID: 27030163
[TBL] [Abstract][Full Text] [Related]
3. Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases.
Oku N
Biol Pharm Bull; 2017; 40(2):119-127. PubMed ID: 28154249
[TBL] [Abstract][Full Text] [Related]
4. [Development of Nano-DDS Carriers for Control of Spatial Distribution Using Multi-color Deep Imaging].
Kawakami S; Suga T
Yakugaku Zasshi; 2020; 140(5):633-640. PubMed ID: 32378663
[TBL] [Abstract][Full Text] [Related]
5. pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon-γ gene lipoplex for efficient cancer immunotherapy.
Yuba E; Kanda Y; Yoshizaki Y; Teranishi R; Harada A; Sugiura K; Izawa T; Yamate J; Sakaguchi N; Koiwai K; Kono K
Biomaterials; 2015 Oct; 67():214-24. PubMed ID: 26222284
[TBL] [Abstract][Full Text] [Related]
6. A dual fluorescent reverse targeting drug delivery system based on curcumin-loaded ovalbumin nanoparticles for allergy treatment.
Liang J; Dong X; Yang A; Zhu D; Kong D; Lv F
Nanomedicine; 2019 Feb; 16():56-68. PubMed ID: 30529561
[TBL] [Abstract][Full Text] [Related]
7. Virosomes: evolution of the liposome as a targeted drug delivery system.
Kaneda Y
Adv Drug Deliv Rev; 2000 Sep; 43(2-3):197-205. PubMed ID: 10967226
[TBL] [Abstract][Full Text] [Related]
8. Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory.
Wang C; Liu P; Zhuang Y; Li P; Jiang B; Pan H; Liu L; Cai L; Ma Y
Vaccine; 2014 Sep; 32(42):5475-83. PubMed ID: 25110295
[TBL] [Abstract][Full Text] [Related]
9. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
10. Targeting and liposomal drug delivery to CD40L expressing T cells for treatment of autoimmune diseases.
Ding Q; Si X; Liu D; Peng J; Tang H; Sun W; Rui M; Chen Q; Wu L; Xu Y
J Control Release; 2015 Jun; 207():86-92. PubMed ID: 25839125
[TBL] [Abstract][Full Text] [Related]
11. Liposomes in biology and medicine.
Schwendener RA
Adv Exp Med Biol; 2007; 620():117-28. PubMed ID: 18217339
[TBL] [Abstract][Full Text] [Related]
12. Design of liposomal formulations for cell targeting.
Nogueira E; Gomes AC; Preto A; Cavaco-Paulo A
Colloids Surf B Biointerfaces; 2015 Dec; 136():514-26. PubMed ID: 26454541
[TBL] [Abstract][Full Text] [Related]
13. Advances and challenges of nanotechnology-based drug delivery systems.
Jiang W; Kim BY; Rutka JT; Chan WC
Expert Opin Drug Deliv; 2007 Nov; 4(6):621-33. PubMed ID: 17970665
[TBL] [Abstract][Full Text] [Related]
14. Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction.
Janicki JJ; Chancellor MB; Kaufman J; Gruber MA; Chancellor DD
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999210
[TBL] [Abstract][Full Text] [Related]
15. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
16. Hitchhiking nanoparticles: Reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes.
Wayteck L; Dewitte H; De Backer L; Breckpot K; Demeester J; De Smedt SC; Raemdonck K
Biomaterials; 2016 Jan; 77():243-54. PubMed ID: 26606450
[TBL] [Abstract][Full Text] [Related]
17. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization.
Wang HW; Jiang PL; Lin SF; Lin HJ; Ou KL; Deng WP; Lee LW; Huang YY; Liang PH; Liu DZ
Acta Biomater; 2013 Mar; 9(3):5681-8. PubMed ID: 23159567
[TBL] [Abstract][Full Text] [Related]
18. [Application of novel drug delivery system, fusogenic liposome, for cancer therapy].
Kunisawa J; Mayumi T
Gan To Kagaku Ryoho; 2001 May; 28(5):577-83. PubMed ID: 11383204
[TBL] [Abstract][Full Text] [Related]
19. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor.
Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y
Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533
[TBL] [Abstract][Full Text] [Related]
20. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
